Rehabilitation evaluation and treatment of patients with chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 252-267

  Li, Li ^a   Gerber, Lynn H ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959705949     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.025     Document Type: Chapter

References (64)

1. Greene WB, Heckman, JD. The clinical measurement of joint motion. 1st ed. Copyright c 1994 by the American Academy of Orthopaedic Surgeons.
2. Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplant. 2000;25 (11):1191–1196.
3. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Onco. 2005;23 (27):6596–6606.
4. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow transplantation: development of the functional assessment of cancer therapy-bone marrow transplant (FACTBMT) scale. Bone Marrow Transplant. 1997;19(4):357–368.
5. Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38 (4):305–310.
6. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
7. McDowell I. Measuring Health: a guide to rating scales and questionnaires. 3rd ed. Oxford, England: Oxford University Press, 2006.
8. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of healthy consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12 (4):375–396.
9. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res. 1999;14 (3):342–350.
10. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinphilia. A new syndrome? J Rheumatol. 1974;1 (Suppl 1):46.
11. Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep. 2002;4(2):113–122.
12. Van Den Bergh V, Tricot G, Fonteyn G, Dom R, Bulcke J. Diffuse fasciitis after bone marrow transplantation. Am J Med. 1987;83 (1):139–143.
13. Kim KW, Yoon CH, Kay CS, Kim HJ, Lee HE, Park SY. Fasciitis after allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia. J Clin Rheumato. 2003;9 (1):33–36.
14. Janin A, Socie G, Devergie A, Aractingi S. Fasciitis in chronic graft-versus-host disease. Ann Intern Med. 1994;120:993–998.
15. O’Laughlin TJ, Klima RR, Kenney DE. Rehabilitation of eosinophilic fasciitis. Am J Phys Med & Rehabil. 1994;73 (4):286–292.
16. Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplantation. Lancet. 2001;357 (9268):1623.
17. Monegal A, Navasa M, Guanabens N et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001;68 (2):83–86
18. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford)2000;39 (12):1383–1389.
19. Rűegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol. 1983;25(5):615–620.
20. Tauchmanova L, Selleri C, Esposito M, et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporosis Int. 2003;14 (12):1013–1019.
21. Tauchmanova L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab.2005;90 (2):627–634.
22. Kananen K, Volin L, Laitinen K, et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone placement with or without pamidronate. J Clin Endocrinal Metab. 2005;90 (7):3877–3885.
23. Grigg AP, Shuttleworth P, Reynolds J, et al.: Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006;91 (10):3835–3843.
24. Jeffcoat M, Watts NB. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. Gen Dent. 2008;56 (1):96–102.
25. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144 (10):753–761
26. Sinaki M. Prevention and treatment of osteoporosis. In: Braddom R, ed. Physical medicine and rehabilitation principles and practice. 3rd ed. W. B. Sauders Company, 2005:929–949.
27. Atkinson K, Cohen M, Biggs J. Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft-versushost- disease after marrow transplantation: effective therapy with hip arthroplasty. Bone Marrow Transplant. 1987;2 (4): 421–426.
28. Tauchmanova L, De Rosa G, Serio B, Fazioli F, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer. 2003;97 (10):2453–2461.
29. Wiesmann A, Pereira P, Bohm P, Faul C, Kanz L, Einsele H. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant. 1998;22(6):565–569.
30. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone transplantation. Am J Med. 1990;89 (6):733–738.
31. Nelson KR, Mcquillen MP. Neurologic complications of graft-versus-host disease. Neurological Clinics. 1988;6 (2): 389–403.
32. Richard S, Fruchtman S, Scigliano E, Skerrett D, Najfeld V, Isola L. An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. Bone Marrow Transplant. 2000;26 (11):1225–1228.
33. Campbell JN Morris PP. Cerebral vasculitis in graft-versushost disease: a case report. AJNR Am J Neur Radiol. 2005;26 9(3):654–656.
34. Greenspan A, Deeg HG, Cottler-Fox M, Sirdofski M, Spitzer TR, Kattah J. Incapacitating peripheral neuropathy as a manifestation of chronic graft versus host disease. Bone Marrow Transplant. 1990;5:349–352.
35. Nagashima T, Sato F, Chuma T, Mano Y, et al. Chronic demyelinating polyneuropathy in graft-versus- host disease following allogeneic bone marrow transplantation. Neuropathology. 2002;22 (1):1–8.
36. Gabriel CM, Goldman JM, Lucas S, Hughes RA. Vasculitis neuropathy in association with chronic graft versus host disease. J Neurol Sci. 1999;168 (1):68–70.
37. Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR. Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology. 1993;43(8):1513–1518
38. Solaro A, Murialdo A, Giunti D, Mancardi G, Uccelli A. Central and peripheral nervous system complications following allogeneic bone marrow transplantation. Eur J of Neurol. 2001;8 (1):77–80.
39. Sullivan KM, Shulman HM, Storb R, et al: Chronic graft-versushost disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57 (2):267–276.
40. Beredjiklian PK, Drummond DS, Dormans JP, Davidson RS, Brock GT, August C. Orthopaedic manifestations of chronic graft-versus-host disease. J Pediatr Orthop. 1998;18 (5):572–575.
41. Currie DM, Ludvigsdottir GK, Diaz CA, Kamani N. Topical treatment of sclerodermoid chronic graft vs host disease. Am J Phys Med Rehabil. 2002;81:143–149.
42. Mock V. Cancer related fatigue. In Given CW, Given B, Champion VL, et al. eds. Evidence-based cancer care and prevention: Behavioral interventions. New York: Springer, 2003:242–273
43. Gielissen MFM, Schattenberg AVM, Verhagen CAHHVM, Rinkes MJ, Bremmers MEJ, Bleijenberg G. Experience of severe fatigue in long-term survivors of stem cell transplantation. Bone Marrow Transplant. 2007;39:595–603.
44. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–611.
45. Winningham ML. Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. Cancer. 2001;92 (Suppl 4):988–997.
46. Prieto JM, Jordi B, Atala J, et al. Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation. Eur J of Cancer. 2006;42 (12):1749–1755.
47. Dimeo FC, Tilmann MHM, Bertz H, Kanz L, Mertelsmann R, Keul J. Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer. 1997;79:1717–1722.
48. Stricker CT, Drake D, Hoyer KA, Mock V. Evidence-based practicefor fatigue management in adults with cancer: exercise as an intervention. Oncol Nurs Forum. 2004;31(5):963–974.
49. Coleman EA, Coon S, Hall-Barrow J, Richards K, Gaylor D, Stewart B. Feasibility of exercise during treatment for multiple myeloma. Cancer Nurs. 2003;26(5):410–419.
50. Wilson RW, Jacobsen PB, Fields KK. Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:721–727.
51. Gergich NLS, Pfalzer LA, McGarvey C, et al. Pre-operative assessment enables early diagnosis and successful treatment of lymphedema. Cancer. 2008 in press.
52. Ramos SM, O’Donnell LS, Kinght G. Edema volume, not timing, is the key to success in lymphedema treatment. AM. J. Surg. 1999;178 (4):311–315.
53. Gary DE. Lymphedema diagnosis and management. J Am Acad Nurse Pract. 2007;19 (2):72–78.
54. Cheville AL, McGarvey CL, Petrek JA, Russo SA, Taylor ME, Thiadens RJ. Lymphedema management. Seminars in Radiation Oncology. 2003;13:290–301.
55. Germain P, Guell A, Marini JF. Muscle strength during bed rest with and without muscle exercise as a countermeasure. Eur J Appl Physiol. 1995;71:342–348.
56. Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine. 1996 Sep;75 (5):279–285.
57. Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003;42 (1):34-39
58. Takahashi K, Kashihara K, Shinagawa K, Yoshino T, Abe K, Harada M. Myositis as a manifestation of chronic graft-versushost disease. Intern Med. 2000;39 (6):482-485
59. Takahashi K, Kashihara K, Shinagawa K, Yoshino T, Abe K, Harada M. Myositis as a manifestation of chronic graft-versushost disease. Intern Med. 2000;39 (6):482–485.
60. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Eng L Med. 1975;292 (8):403–407.
61. Shepard RJ, Shek PN. Autoimmune disorders, physical activity and training with particular reference to rheumatoid arthritis. Exerc Immunol Rev. 1997;3:53–67.
62. Smith CI, Aarli JA, Biberfeld P, et al. Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med. 1983;309 (25):1565–1568.
63. Tse S, Sunders EF, Silverman E, Vajsar J, Becker L, Meaney B. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Bone Marrow Transplant. 1999;23 (4):397–399.
64. Grant J, Young MA, Pidcock FS, Christensen JR. Physical medicine and rehabilitation management of chronic graft versus host disease. Rehabilitation Oncology. 1997;15 (3): 13–15.